TickrTrends All fair-value coverage
X Reddit StockTwits

OrthoPediatrics Corp. (KIDS) fair value analysis

Nasdaq · Updated 2026-10-19

KIDS price how computed

Last close $21.95 -$0.62 (-2.75%) since 2026-10-15

1M +0.60%3M +12.62%6M +31.83%1Y +23.31%

High $22.89Low $21.652026-09-18 → 2026-10-16High $26.50Low $18.722026-07-21 → 2026-10-16High $26.50Low $14.642026-04-20 → 2026-10-16High $26.50Low $14.642025-10-16 → 2026-10-16

Valuation status

No fair-value estimate yet

KIDS has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.

Forward Fair Value needs both, so TickrTrends publishes no verdict for KIDS yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.

Last price
$21.95
Sector
Healthcare
12-month range
$14.64–$26.50
Market cap
$573M
From 52-week high
-17.2%
Shares outstanding
26.1M
Rank in Healthcare by quality score
#84 of 301

Last price is the 2026-10-16 close; the chart runs through 2026-10-16.

OrthoPediatrics Corp. is a medical device company that designs, manufactures, and markets orthopedic implants and instruments specifically for pediatric patients. The company operates primarily in the United States and serves orthopedic surgeons who treat children with bone and joint conditions.

KIDS currently ranks #84 of 301 Healthcare stocks by quality score.

Fundamentals (4 quarters) how computed

Market cap
$573M
P/E (trailing)
n/m
Revenue (TTM)
$253M
Net margin
-15.7%
EPS (TTM)
$-1.18
Gross margin
74.3%
Debt / equity
0.27
Revenue growth (3-yr avg)
25.5%
Shares outstanding
26.1M

Derived indicators how computed

Quality grade
C
Margin trend
Expanding
52-week position
The upper-middle quarter of its range

Technicals how computed

RSI (14-day)
50 · neutral
50-day average
$23.09
200-day average
$19.19
Moving-average state
50-day above 200-day (golden cross state); price between the averages

Earnings how computed

Next earnings report
2026-10-27 (post-market)
Last 8 quarters vs consensus
7 beat, 1 missed
Quarter by quarter
2026-06 ▲ beat (+16.1%)
2026-03 ▲ beat (+4.5%)
2025-12 ▲ beat (+29.7%)
2025-09 ▲ beat (+7.7%)
2025-06 ▲ beat (+60.7%)
2025-03 ▲ beat (+9.3%)
2024-12 ▼ miss (-13.0%)
2024-09 ▲ beat (+5.3%)

Analyst consensus how computed

This is not TickrTrends' verdict.

Analyst ratings
8 buy · 1 hold · 0 sell (9 analysts)
Consensus lean
Buy-leaning
Consensus price target
$27.5
Target vs last price
+25.3%

What our data shows for KIDS

What subscribers see

Explore the fair value screener →

Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.

What people are saying

Follow the KIDS conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

Frequently asked questions

Is KIDS stock undervalued?

TickrTrends has no fair-value estimate for KIDS yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.

What is KIDS's TickrTrends verdict?

KIDS is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.

How does KIDS compare to other Healthcare stocks?

KIDS ranks #84 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.

Is KIDS overbought or oversold?

KIDS's 14-day RSI is in neutral territory - neither overbought nor oversold.

When does KIDS report earnings next?

KIDS's next earnings report is scheduled for 2026-10-27 (post-market), per the published earnings calendar.

Does KIDS usually beat earnings estimates?

Over its last 8 reported quarters KIDS beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.

What do analysts say about KIDS?

Of 9 analysts covering KIDS, 8 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $27.5 (+25.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.

All Healthcare fair-value coverage →

Head-to-head comparisons

KIDS vs LEGN · KIDS vs NVAX · KIDS vs TMO · KIDS vs ZTS